Varicella Clinical Trial
Official title:
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
A study team with extensive experience in immunization delivery research will evaluate the effectiveness of vaccination reminder/recall systems for adolescent patients in five types of clinical settings including: urban pediatric, urban family medicine and rural family medicine practices, public pediatric clinics, and school-based health centers. Randomized controlled trials of reminder/recall for adolescents will be conducted at each type of site, with randomization at the level of the patient.
Although patient reminder/recall systems have been shown to be effective at improving
vaccination coverage levels for infants and younger children, little is known about the
effectiveness of such systems for increasing immunization rates in adolescent populations.
The process of reminder/recall in adolescents, and vaccination of adolescents overall,
presents particular challenges. Adolescents are less likely to routinely access health care
compared to younger children and adults. In addition, other obstacles such as lack of health
insurance, missed opportunities for vaccination during health care visits, and the
scattering of immunization records across multiple providers have posed major challenges in
the vaccination of adolescents. Issues of parental consent for vaccination can also be
problematic, given that adolescents may present for care without their parents accompanying
them. These and other barriers to immunization may reduce the effectiveness of
reminder/recall for adolescents. In the current research study, a study team with extensive
experience in immunization delivery research will investigate the ability of pediatricians
and family physicians in a number of different practice settings to implement a
reminder/recall system for their adolescent patient populations. In addition, we will be
able to examine the effectiveness of reminder/recall originating at public school-based
health centers, an innovative strategy that has not previously been reported. Randomized
controlled trials of reminder/recall for adolescents will be conducted at each type of site.
The study team will track important process measures during reminder/recall including the
percentage of the eligible population who actually received intervention; percentage with
incorrect addresses; percentage with incorrect or disconnected phones; percentage actually
up-to-date but incorrectly recalled; missed vaccination opportunities; and invalid doses of
vaccines administered. In this way, we will be able to not only determine the degree to
which reminder/recall was successful for adolescents, but also identify impediments to
success, which will provide a foundation for future efforts. Our study will also investigate
the cost of establishing and operating a reminder/recall system for adolescents in each type
of clinical setting.
Major Hypotheses
1. Reminder/recall of adolescents will result in an increased rate of receipt of
immunizations in private settings of approximately 10 percentage points
2. Reminder/recall will result in a greater rate of receipt of immunizations when patients
in public settings have access to a school-based health center (SBHC) compared to when
they do not have access to a SBHC
3. Reminder/recall originating at SBHC sites will result in the highest efficacy of
reminder/recall among all the types of clinical sites
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00792623 -
Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).
|
Phase 2 | |
Enrolling by invitation |
NCT05015686 -
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
|
Phase 3 | |
Completed |
NCT00092430 -
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
|
Phase 3 | |
Completed |
NCT00384397 -
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT00226499 -
Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox
|
Phase 3 | |
Completed |
NCT00402831 -
ProQuad® Intramuscular vs Subcutaneous
|
Phase 3 | |
Not yet recruiting |
NCT06068608 -
A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy
|
Phase 1 | |
Completed |
NCT00560755 -
Safety Study of ProQuad® rHA in Infants (V221-037)
|
Phase 3 | |
Terminated |
NCT00258726 -
Immune Responses to Two Dose Varivax +/- MMR-II
|
Phase 1/Phase 2 | |
Completed |
NCT03239873 -
Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)
|
Phase 3 | |
Completed |
NCT00751348 -
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
|
Phase 3 | |
Completed |
NCT00969436 -
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
|
Phase 3 | |
Completed |
NCT00566527 -
Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
|
Phase 3 | |
Completed |
NCT01390857 -
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)
|
N/A | |
Completed |
NCT00127010 -
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
|
Phase 3 | |
Completed |
NCT00578175 -
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
|
Phase 2 | |
Completed |
NCT00568334 -
Study of Two Formulations of GSK Biologicals' Varicella Vaccine
|
Phase 2 | |
Completed |
NCT03114982 -
The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age
|
Phase 2 | |
Completed |
NCT00483574 -
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
|
Phase 3 | |
Completed |
NCT00127023 -
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
|
Phase 3 |